OBJECTIVE: To assess the feasibility and acceptance of a postal survey to measure human papillomavirus (HPV) prevalence and monitor vaccine impact, using self-taken specimens from young women who do not attend their first cervical screening appointment. METHODS: Focus groups informed the survey design identifying factors that would influence acceptability. Postal testing kits were sent to a nationally representative sample of unscreened women. Overall response rate, the influence of different specimen types (urine or vaginal swab) and the receipt of a reminder letter on participation were calculated. Specimens were tested anonymously for HPV. Individual test results were not provided. RESULTS: Of 5500 kits sent, 725 were returned (13.2%). Fifty-two women actively opted out. There was a higher return rate for urine kits (13.7% vs 12%) and from those who received a reminder letter (15.5% vs 12.2%). Response was influenced by deprivation (10.3% in the most deprived quintile vs 16.2% in the least). Overall weighted HPV prevalence was 35.9% (40.0% from swab specimens and 31.9% from urine). CONCLUSIONS: Some women were willing to participate in anonymised postal testing. However, the low uptake means that HPV prevalence results are difficult to interpret for ongoing surveillance. Monitoring HPV vaccine impact outwith the cervical screening programme remains challenging.
OBJECTIVE: To assess the feasibility and acceptance of a postal survey to measure human papillomavirus (HPV) prevalence and monitor vaccine impact, using self-taken specimens from young women who do not attend their first cervical screening appointment. METHODS: Focus groups informed the survey design identifying factors that would influence acceptability. Postal testing kits were sent to a nationally representative sample of unscreened women. Overall response rate, the influence of different specimen types (urine or vaginal swab) and the receipt of a reminder letter on participation were calculated. Specimens were tested anonymously for HPV. Individual test results were not provided. RESULTS: Of 5500 kits sent, 725 were returned (13.2%). Fifty-two women actively opted out. There was a higher return rate for urine kits (13.7% vs 12%) and from those who received a reminder letter (15.5% vs 12.2%). Response was influenced by deprivation (10.3% in the most deprived quintile vs 16.2% in the least). Overall weighted HPV prevalence was 35.9% (40.0% from swab specimens and 31.9% from urine). CONCLUSIONS: Some women were willing to participate in anonymised postal testing. However, the low uptake means that HPV prevalence results are difficult to interpret for ongoing surveillance. Monitoring HPV vaccine impact outwith the cervical screening programme remains challenging.
Authors: Eliane Rohner; F Hunter McGuire; Yutong Liu; Quefeng Li; Kate Miele; Samveg A Desai; John W Schmitt; Andrea Knittel; Julie A E Nelson; Claire Edelman; Vijay Sivaraman; Anna Baker; LaHoma S Romocki; Lisa Rahangdale; Jennifer S Smith Journal: J Womens Health (Larchmt) Date: 2020-03-26 Impact factor: 2.681
Authors: Kimberley Kavanagh; Katy Sinka; Kate Cuschieri; John Love; Alison Potts; Kevin G J Pollock; Heather Cubie; Martin Donaghy; Chris Robertson Journal: BMC Infect Dis Date: 2013-11-05 Impact factor: 3.090
Authors: Ross L Cameron; Kimberley Kavanagh; Jiafeng Pan; John Love; Kate Cuschieri; Chris Robertson; Syed Ahmed; Timothy Palmer; Kevin G J Pollock Journal: Emerg Infect Dis Date: 2016-01 Impact factor: 6.883
Authors: David I Conway; Chris Robertson; Heather Gray; Linda Young; Lisa M McDaid; Andrew J Winter; Christine Campbell; Jiafeng Pan; Kimberley Kavanagh; Sharon Kean; Ramya Bhatia; Heather Cubie; Jan E Clarkson; Jeremy Bagg; Kevin G Pollock; Kate Cuschieri Journal: PLoS One Date: 2016-11-18 Impact factor: 3.240
Authors: Donna M Lecky; Deborah Nakiboneka-Ssenabulya; Tom Nichols; Peter Hawkey; Kim Turner; Keun-Taik Chung; Mike Thomas; Helen Lucy Thomas; Li Xu McCrae; Sahida Shabir; Susan Manzoor; Adela Alvarez-Buylla; Steve Smith; Cliodna McNulty Journal: BMJ Open Date: 2017-12-10 Impact factor: 2.692
Authors: Tor Molden; Berit Feiring; Ole Herman Ambur; Irene K Christiansen; Mona Hansen; Ida Laake; Roger Meisal; Ellen Myrvang; Christine Monceyron Jonassen; Lill Trogstad Journal: Papillomavirus Res Date: 2016-05-20
Authors: K Kavanagh; K G J Pollock; A Potts; J Love; K Cuschieri; H Cubie; C Robertson; M Donaghy Journal: Br J Cancer Date: 2014-04-15 Impact factor: 7.640